RxDoctor Payments Data

Bethany Duff, MD

Family Medicine · Manhattan, KSNPI 1750675724

Payments from drug & device makers

$7,607in general payments, 2019–2025

Across 500 payments — averaging $15.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$817
  • Lilly USA, LLC$808
  • Pfizer$788
  • AstraZeneca$648
  • Amgen$631
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$7,51699%
  • Education$911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,607 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$180,331
Medicare patients
212
Services billed
5,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide46$61,038
JardianceEmpagliflozin61$59,004
EliquisApixaban59$56,692
MounjaroTirzepatide28$43,591
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$42,864
FarxigaDapagliflozin Propanediol39$30,487
OzempicSemaglutide19$24,865
JanuviaSitagliptin Phosphate12$16,076
LinzessLinaclotide23$12,442
AbrysvoRsv Vacc, Pref A And Pref B/Pf38$12,038
MyrbetriqMirabegron16$10,759
XareltoRivaroxaban11$8,088
DayvigoLemborexant11$3,460
Atorvastatin Calcium208$2,344
Metoprolol Succinate84$2,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$808$104,62974 claims
PfizerEliquis, Abrysvo$788$68,73097 claims
Boehringer IngelheimJardiance$329$59,00461 claims
GSKTrelegy Ellipta$270$42,86446 claims
AstraZenecaFarxiga$648$30,48739 claims
Novo NordiskOzempic$817$24,86519 claims
MerckJanuvia$100$16,07612 claims
AbbVieLinzess$1,058$12,44223 claims
Astellas Pharma US IncMyrbetriq$164$10,75916 claims
Johnson & JohnsonXarelto$64$8,08811 claims
Eisai Inc.Dayvigo$36$3,46011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Manhattan

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →